Cogentix Medical Inc  

(Public, NASDAQ:CGNT)   Watch this stock  
Find more results for NASDAQ:VSCI
0.00 (0.00%)
Nov 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.46 - 1.58
52 week 1.10 - 6.10
Open 1.56
Vol / Avg. 0.00/49,709.00
Mkt cap 39.35M
P/E     -
Div/yield     -
EPS -0.51
Shares 26.06M
Beta 1.16
Inst. own 34%
Feb 2, 2016
Q3 2016 Cogentix Medical Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 3, 2015
Q2 2016 Cogentix Medical Inc Earnings Call
Nov 3, 2015
Q2 2016 Cogentix Medical Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2015
Net profit margin -20.02% -29.06%
Operating margin -16.96% -28.83%
EBITD margin - -27.78%
Return on average assets -18.53% -20.82%
Return on average equity -51.49% -42.87%
Employees 211 -
CDP Score - -


5420 Feltl Rd
MINNETONKA, MN 55343-7982
United States - Map
+1-952-4266140 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cogentix Medical, Inc., formerly Vision-Sciences, Inc., is a medical device company. The Company designs, develops, manufactures and markets products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, EndoSheath technology. The Company produces and markets Endoscopes, such as cystoscopes, ureteroscopes, laryngoscopes, otoscopes, sinuscopes, trans-nasal esophagoscopy (TNE) and bronchoscopes for medical use and borescopes for industrial use, and digital processing units (DPU). The Company offers Urgent PC Neuromodulation System, a nerve stimulation device that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). It also offers Macroplastique, an injectable, urethral bulking agent for the treatment of adult female stress urinary incontinence. It markets additional bulking agents: PTQ for the treatment of fecal incontinence and the VOX for vocal cord augmentation.

Officers and directors

Robert C. Kill Chairman of the Board, President, Chief Executive Officer
Age: 51
Bio & Compensation  - Reuters
Brett A. Reynolds Senior Vice President, Chief Financial Officer, Corporate Secretary
Age: 45
Bio & Compensation  - Reuters
Darin Hammers Senior Vice President - Global Sales and Marketing
Bio & Compensation  - Reuters
James P. Stauner Lead Independent Director
Age: 60
Bio & Compensation  - Reuters
Kenneth H. Paulus Director
Age: 55
Bio & Compensation  - Reuters
Cheryl Pegus M.D. Director
Age: 51
Bio & Compensation  - Reuters
Lewis C. Pell Director
Age: 71
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Kevin H. Roche Director
Age: 63
Bio & Compensation  - Reuters